Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Efficacy of Autologous Stem-Cell Transplantation in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma in the Rituximab Era. A Multicenter Geltamo Study.

Blood (2012) 120 (21): 3142.

https://doi.org/10.1182/blood.V120.21.3142.3142

Published: 2012

Journal Articles

Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial

Blood (2012) 120 (21): 334.

https://doi.org/10.1182/blood.V120.21.334.334

Published: 2012

Journal Articles

Whole Bone Marrow (BM) Immunophenotypic Profiling for the Identification of Newly Diagnosed Symptomatic Multiple Myeloma (MM) Patients with an MGUS-Like Signature Associated with Long-Term Disease Control (LTDC)

Blood (2012) 120 (21): 3949.

https://doi.org/10.1182/blood.V120.21.3949.3949

Published: 2012

Journal Articles

Maintenance Therapy with Bortezomib Plus Thalidomide (VT) or Bortezomib Plus Prednisone (VP) In Elderly Myeloma Patients Included In the GEM2005MAS65 Spanish Randomized Trial

María-Victoria Mateos, MD, PhD, Albert Oriol, Ana-Isabel Teruel, Enrique Bengoechea, Montse Pérez, Javier López, Joaquín Díaz-Mediavilla, Jose Mariano Hernández, Felipe de Arriba, Yolanda Gonzalez, Joan Bladé, MD, Juan José Lahuerta, JesÃ°s F. San Miguel

Blood (2011) 118 (21): 477.

https://doi.org/10.1182/blood.V118.21.477.477

Published: 2011

Journal Articles

Multiparameter Flow Cytometry (MFC) Evaluation of Plasma Cell (PC) DNA Ploidy Status and Proliferative Rate in 595 Multiple Myeloma (MM) Patients (pts) Included in the Spanish GEM2000 and GEM2005<65years Trials: Clinical Value and Biological Insights,

Blood (2011) 118 (21): 3938.

https://doi.org/10.1182/blood.V118.21.3938.3938

Published: 2011

Journal Articles

High-Risk Cytogenetics and Persistent Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) Predict Unsustained Complete Response (CR) After Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)

Blood (2011) 118 (21): 630.

https://doi.org/10.1182/blood.V118.21.630.630

Published: 2011

Journal Articles

A Phase III PETHEMA/GEM Randomized Trial of Postransplant (ASCT) Maintenance in Multiple Myeloma: Superiority of Bortezomib/Thalidomide Compared with Thalidomide and Alfa-2b Interferon,

Blood (2011) 118 (21): 3962.

https://doi.org/10.1182/blood.V118.21.3962.3962

Published: 2011

Journal Articles

Influence of Genetic Polymorphisms in CYP1A2 , CYP2C19, CYP3A4 , GSTP1 , MDR1 and PSMB5 Genes in Toxicity and Response to Induction Therapy in Multiple Myeloma Patients Included in the Trial of the Spanish PETHEMA/GEM 05 for Newly Diagnosed MM Elderly Patients (Age 65 or More)

Blood (2011) 118 (21): 1412.

https://doi.org/10.1182/blood.V118.21.1412.1412

Published: 2011

Journal Articles

Analysis of Immunophenotypic Response (IR) by Multiparameter Flow Cytometry In 516 Myeloma Patients Included In Three Consecutive Spanish Trials

Blood (2010) 116 (21): 1910.

https://doi.org/10.1182/blood.V116.21.1910.1910

Published: 2010

Journal Articles

A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib

Blood (2010) 116 (21): 307.

https://doi.org/10.1182/blood.V116.21.307.307

Published: 2010

Journal Articles

Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination

Blood (2010) 116 (21): 309.

https://doi.org/10.1182/blood.V116.21.309.309

Published: 2010

Journal Articles

Salvage Therapy with Chemotherapy- or Arsenic Trioxide-Based Regimens for Acute Promyelocytic Leukemia in First Relapse.

Pau Montesinos, Jordi Esteve, Edo Vellenga, Concha Rivas, Salut Brunet, Montserrat Arnan, Jose D. Gonzalez, Pedro Sanchez, Joaquín Díaz-Mediavilla, Amparo Verdeguer, Lourdes Escoda, Elena Amutio, Vicente Rubio, Inmaculada Perez, Ramon Guardia, Javier Bueno, Bob Lowenberg, Miguel A. Sanz

Blood (2009) 114 (22): 1062.

https://doi.org/10.1182/blood.V114.22.1062.1062

Published: 2009

Journal Articles

Risk-Adapted Treatment of Acute Promyelocytic Leukemia: Results of the PETHEMA LPA2005 Trial Using All- Trans Retinoic Acid and Anthracycline with Cytarabine for High-Risk Patients

Miguel A. Sanz, MD, PhD, Pau Montesinos, Aleksandra Holowiecka, Gustavo Milone, Chelo Rayon, Elena de Lisa, Javier de la Serna, Salut Brunet, Angel Leon, Isabel Krsnik, Concha Rivas, Jose M. Ribera, Jose Gonzalez, Joaquín Díaz- Mediavilla, Javier Bueno, Jose David Gonzalez, Juan Bergua, Marcos Gonzalez

Blood (2008) 112 (11): 138.

https://doi.org/10.1182/blood.V112.11.138.138

Published: 2008

Journal Articles

Thalidomide/Dexamethasone (TD) Vs. Bortezomib(Velcade®)/Thalidomide/Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade® As Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Younger Patients with Multiple Myeloma (MM): First Results of a Prospective Phase III PETHEMA/Gem Trial

Laura Rosinol, M. Teresa Cibeira, Joaquin Martinez, Maria Victoria Mateos, Ma José Terol, Javier de la Rubia, Luis Palomera, Felipe de Arriba, Albert Oriol, Adrian Alegre, Juan Besalduch, Raquel de Paz, José Garcia-Laraña, Joaquín Díaz-Mediavilla, Anna Sureda, Juan José Lahuerta, J.F. San Miguel, Joan Blade

Blood (2008) 112 (11): 654.

https://doi.org/10.1182/blood.V112.11.654.654

Published: 2008

Journal Articles

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

Blood (2006) 108 (7): 2165–2172.

https://doi.org/10.1182/blood-2006-04-019778

Published: 2006

Journal Articles

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA

Blood (2005) 106 (12): 3755–3759.

https://doi.org/10.1182/blood-2005-03-1301

Published: 2005

Journal Articles

All- trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia

Miguel A. Sanz, Edo Vellenga, Chelo Rayón, Joaquín Díaz-Mediavilla, Concha Rivas, Elena Amutio, Jesús Arias, Guillermo Debén, Andrés Novo, Juan Bergua, Javier de la Serna, Javier Bueno, Silvia Negri, José M. Beltrán de Heredia, Guillermo Martín

Blood (2004) 104 (12): 3490–3493.

https://doi.org/10.1182/blood-2004-04-1642

Published: 2004

Journal Articles

Minimal Residual Disease (MRD) Evaluation by Flow Cytometry in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.

Maria-Belen Vidriales, MD, PhD, Jose J. Pérez, Consuelo López-Berges, MD, PhD, Norma C. Gutierrez, MD, PhD, Juana Ciudad, PhD, Lourdes Vazquez, MD, PhD, Consuelo del Cañizo, MD, PhD, Joaquín Díaz-Mediavilla, MD, PhD, Javier Fernández-Calvo, MD, Fernando Ramos, MD, PhD, María Jesús Rodriguez, MD, PhD, María José Calmuntia, MD, PhD, Alberto Orfao, MD, PhD, Jesús San Miguel, MD, PhD

Blood (2004) 104 (11): 1103.

https://doi.org/10.1182/blood.V104.11.1103.1103

Published: 2004

Journal Articles

Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome

Jesús F. San Miguel, Julia Almeida, Gema Mateo, Joan Bladé, Consuelo López-Berges, Dolores Caballero, José Hernández, Marı́a Jesús Moro, Javier Fernández-Calvo, Joaquı́n Dı́az-Mediavilla, Luis Palomera, Alberto Orfao

Blood (2002) 99 (5): 1853–1856.

https://doi.org/10.1182/blood.V99.5.1853

Published: 2002

Journal Articles

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

Jesús F. San Miguel, Marı́a B. Vidriales, Consuelo López-Berges, Joaquı́n Dı́az-Mediavilla, Norma Gutiérrez, Consuelo Cañizo, Fernando Ramos, Marı́a J. Calmuntia, José J. Pérez, Marcos González, Alberto Orfao

Blood (2001) 98 (6): 1746–1751.

https://doi.org/10.1182/blood.V98.6.1746

Published: 2001

NARROW

Efficacy of Autologous Stem-Cell Transplantation in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma in the Rituximab Era. A Multicenter Geltamo Study.

Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial

Whole Bone Marrow (BM) Immunophenotypic Profiling for the Identification of Newly Diagnosed Symptomatic Multiple Myeloma (MM) Patients with an MGUS-Like Signature Associated with Long-Term Disease Control (LTDC)

Maintenance Therapy with Bortezomib Plus Thalidomide (VT) or Bortezomib Plus Prednisone (VP) In Elderly Myeloma Patients Included In the GEM2005MAS65 Spanish Randomized Trial

Multiparameter Flow Cytometry (MFC) Evaluation of Plasma Cell (PC) DNA Ploidy Status and Proliferative Rate in 595 Multiple Myeloma (MM) Patients (pts) Included in the Spanish GEM2000 and GEM2005<65years Trials: Clinical Value and Biological Insights,

High-Risk Cytogenetics and Persistent Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) Predict Unsustained Complete Response (CR) After Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)

A Phase III PETHEMA/GEM Randomized Trial of Postransplant (ASCT) Maintenance in Multiple Myeloma: Superiority of Bortezomib/Thalidomide Compared with Thalidomide and Alfa-2b Interferon,

Influence of Genetic Polymorphisms in CYP1A2 , CYP2C19, CYP3A4 , GSTP1 , MDR1 and PSMB5 Genes in Toxicity and Response to Induction Therapy in Multiple Myeloma Patients Included in the Trial of the Spanish PETHEMA/GEM 05 for Newly Diagnosed MM Elderly Patients (Age 65 or More)

Analysis of Immunophenotypic Response (IR) by Multiparameter Flow Cytometry In 516 Myeloma Patients Included In Three Consecutive Spanish Trials

A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib

Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination

Salvage Therapy with Chemotherapy- or Arsenic Trioxide-Based Regimens for Acute Promyelocytic Leukemia in First Relapse.

Risk-Adapted Treatment of Acute Promyelocytic Leukemia: Results of the PETHEMA LPA2005 Trial Using All- Trans Retinoic Acid and Anthracycline with Cytarabine for High-Risk Patients

Thalidomide/Dexamethasone (TD) Vs. Bortezomib(Velcade®)/Thalidomide/Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade® As Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Younger Patients with Multiple Myeloma (MM): First Results of a Prospective Phase III PETHEMA/Gem Trial

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA

All- trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia

Minimal Residual Disease (MRD) Evaluation by Flow Cytometry in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.

Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only